

# *Joanne Petruso RN, MSN*

---

## **Office Address:**

Nevada Access to Research and Education Society  
Nevada AIDS Research and Education Society  
2300 S. Rancho Dr., Suite #203  
Las Vegas, NV 89102  
Phone: (702) 384-9101  
Fax: (702) 384-9109  
E-mail: [nares2lv@aol.com](mailto:nares2lv@aol.com)

Wellness Center  
2300 S. Rancho Dr.  
Suite 205  
Las Vegas, NV 89102  
Phone: (702) 383-2691  
Fax: (702) 388-4186

Pulmonary Associates  
7200 Cathedral Rock Drive  
Suite 220  
Las Vegas, NV 89128  
Phone: (702) 307-7707  
Fax: (702) 307-7706

Pulmonary Associates  
4 Sunset Way  
Building A- Suite 3  
Henderson, NV 89014  
Phone: (702) 434-9690  
Fax: (702) 436-7266

## **Employment History:**

Nov.2006 – Present	Research Coordinator Pulmonary Associates 7200 Cathedral Rock Drive Suite 220 Las Vegas, NV 89128
Nov. 2006 – Present	Research Coordinator Pulmonary Associates 4 Sunset Way, Bldg.A-Ste. 3 Las Vegas, NV 89104
Sept. 2003 – Present	Research Coordinator Wellness Center 2300 S. Rancho Dr. Suite 205 Las Vegas, NV 89102
Sept. 2003 – Present	Research Coordinator Nevada Access to Research and Education Society Nevada AIDS Research and Education Society 2300 S. Rancho Dr. #203 Las Vegas, NV 89102

## Employment History Continued:

Dec. 1999 – Oct. 2006	Research Coordinator Allergy & Asthma Associates 4000 East Charleston Blvd. Suite 100 Las Vegas, NV 89104
Dec. 1999 – Sept 2003	Research Coordinator Nevada Access to Research and Education Society Nevada AIDS Research and Education Society 2300 W. Charleston Blvd #259 Las Vegas, NV 89102
Aug. 1997 – Dec. 2000	Research Coordinator Nevada Clinical Research 2020 Goldring #206 Las Vegas, NV 89102
May 1997 – Aug. 1997	Research Coordinator Southwest Medical Associates, Inc. 2316 W. Charleston Blvd #170 Las Vegas, NV 89102
Oct. 1995 – May 1997	Clinical Process Specialist and Research Assistant Health Insight 901 Rancho Blvd Las Vegas, NV 89106
Aug. 1994 – Jan. 1996	Hospital Case Manager Sierra Health and Life 2720 N. Tenaya Way Las Vegas, NV 89128
1989	Staff Nurse, Mobile Units San Diego Blood Bank
1977 – 1981	Relief Charge and Staff Nurse Intensive Care Unit Sunrise Hospital and Medical Center Las Vegas, NV 89109

## **Licensing:**

1977 – Present  
Registered Nurse  
State of Nevada RN#08618

## **Certifications:**

April 2005  
“IRB 101 At Your Doorstep” The History and Ethics of Human Subjects Research. University Medical Center, Las Vegas, Nevada

July 2001 - Present  
IATA Regulation and Hazardous Material (49CFR and Canadian TDR) Certification Program  
Saf-T-Pak Inc Course in Shipping Hazardous Goods  
Las Vegas, Nevada.

2001  
Human Participant Protection Education for Research Teams  
National Institutes of Health

2001  
Good Clinical Practices  
Bristol Myers Squibb

## **Education:**

2001  
Masters of Science in Nursing  
University of Nevada, Las Vegas  
Las Vegas, NV

1994  
Bachelors of Science in Nursing  
University of Nevada, Las Vegas  
Las Vegas, NV

1977  
Bachelors of Arts in Psychology  
University of Nevada, Las Vegas  
Las Vegas, NV

1977  
Associate Degree in Nursing  
University of Nevada, Las Vegas  
Las Vegas, NV

## **Honors:**

1992 -Present  
Sigma Theta Tau  
International Nursing Honor Society

## **Community Service:**

2001-2002	Volunteer Nurse Camp Cartwheel Kids Cancer Camp
1996 – 1998	Volunteer Nurse Camp Super Kids Asthma Camp American Lung Association
1996	Human Subjects Rights Committee University Of Nevada, Nursing Department Las Vegas, NV

## **Research:**

9188US/0017. Accept-Accolate. An open label, noncomparative, multicenter trial to evaluate Accolate in patients with asthma. Investigator.

GFXA4003. A randomized, double-blind, multicenter comparison of the efficacy and safety of Grepafloxacin (Raxar) 400mg or 600mg once daily and Clarithromycin (Biaxin) 500mg twice daily in the treatment of patients with acute bacterial exacerbation of chronic bronchitis. GlaxoWellcome. Investigator.

066-0700. Eradication of helicobacter pylori infection and the treatment of active peptic ulcer disease. Pfizer. Investigator.

066-0701. Eradication of helicobacter pylori infection in patients with a history of healed peptic ulcer disease. Pfizer. Investigator.

TH97-0110 A multicenter, randomized, double-blind, parallel study comparing the efficacy and safety of tramadol hydrochloride controlled-release tablets versus ultram versus placebo in patients with patients with chronic back pain. Purdue Pharma. Investigator.

TH97-0111. A multicenter, randomized, double-blind, parallel study comparing the efficacy and safety of tramadol hydrochloride controlled-release tablets versus ultram versus placebo in patients with chronic pain due to osteoarthritis of the knee. Purdue Pharma. Investigator

N49-98-02-082. A single dose, double-blind, placebo-controlled comparison of the analgesic activity of SC58635 200mg, Hydrocodone 10mg/Acetaminophen 1000mg and Placebo in post-orthopedic surgical patients (total hip and knee replacement surgery). Searle. Investigator.

## **Research Continued:**

N49-98-02-086. A double-blind, placebo-controlled single dose and active controlled multiple dose assessment of the analgesic activity of SC58635 200mg, Hydrocodone 10mg/Acetaminophen 1000mg, and placebo in post-orthopedic surgical patients (general orthopedic surgery). Searle. Investigator.

N49-98-02-087. Clinical protocol for a multicenter, double-blind, placebo controlled comparison study of the efficacy of SC58635 200mg daily versus SC58635 100mg twice daily in treating the signs and symptoms of osteoarthritis of the knee. Searle. Investigator.

DE 009. A multicenter randomized placebo controlled phase II study of the Human Anti-TNF Antibody D2E7 administered as subcutaneous injections in rheumatoid arthritis patients treated with methotrexate. (LU 200134). Investigator, Knoll Pharmaceutical Comp, Dec 1999.

O99009 Transdermal oxybutynin in patients with urge urinary incontinence: A 12 week multicenter, randomized, double-blind, placebo-controlled study with a 12-week open-label, dose-titration, safety extension. Watson Laboratories. Investigator, Jan 2000.

SNG477. A randomized, double-blind, multicenter study to evaluate the effect of adding either Montelukast Sodium or Salmeterol Xinafoate to inhaled Fluticasone in adult asthmatics. Investigator. Merck and Co. Inc.

A randomized, double-blind, placebo controlled, parallel-group 12 week trial evaluating the safety and efficacy of Salmeterol/Fluticasone Propionate combination in GR106642X MDI vs. Salmeterol, Fluticasone or Placebo in adolescent and adult subjects with asthma. Investigator. Glaxo Wellcome. 2000.

HMP-3006 A Study of the Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release (HHER) Compared to Placebo in Patients with Chronic Pain. Purdue Pharma L.P. Investigator. Jan 2001.

O00011. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing Oxybutynin Transdermal Systems versus Tolterodine Long Acting Capsules in Patients with Overactive Bladder. Watson Laboratories. Investigator May 2001.

SPORTIF V. Efficacy and safety study of the oral direct thrombin inhibitor H376/95 compared with dose-adjusted warfarin (Coumadin) in the prevention of stroke and systemic embolic events in patients with atrial fibrillation. Astra Zeneca. Investigator. 2001.

## Research Continued:

N91-00-02-079. Clinical protocol for a randomized, double-blind, placebo controlled, parallel group comparison of the analgesic activity of valdecoxib (SC-65872) 20mg bid versus diclofenac 75mg bid in patients with chronic cancer pain. Pharmacia/Pfizer. Investigator. 2001.

N49-01-02. clinical protocol for the assessment of the efficacy of treatment by Celecoxib 200mg QD and 400mg QD on the symptoms of ankylosing spondylitis compared to naproxen and placebo. Investigator. Pharmacia. 2001.

HMR3647A/3014. Randomized, open-label, multicenter trial of the safety and effectiveness of Oral Telithromycin (Ketek) and amoxicillin/clavulanic acid (Augmentin) in outpatients with respiratory tract infections in usual care settings. Aventis Pharmaceuticals, Inc. Investigator. 2001.

NAVIGATOR Nateglinide/CDJN608B. A multinational, randomized, double-blind, placebo-controlled, forced-titration, 2 X 2 factorial design study of the efficacy and safety of long term administration of nateglinide and valsartan in the prevention of diabetes and cardiovascular outcomes in subjects with impaired glucose tolerance. Novartis. Investigator.

CLAF237A 2203. A 12 week, multicenter, double-blind, randomized, parallel-group, dose-ranging study to assess the efficacy, safety and tolerability of LAF237 25mg bid, 25mg, 50mg, 100mg qd compared to placebo in patients with type 2 diabetes. Novartis. Investigator.

SAS40036. Multicenter, randomized, double blind, double dummy, parallel group 16 week comparison of asthma control in adolescents and adults receiving either Fluticasone Propionate/Salmeterol Diskus 100/50mcg bid, Fluticasone Propionate Diskus 100mcg bid, Salmeterol 50mcg bid or montelukast 10mg qd. GlaxoSmithKline. Investigator.

M016455P/3003. A multicenter, open label, randomized, parallel group study to assess the long term safety, performance, and efficacy of fexofenadine compared to montelukast in subjects with asthma. Aventis. Investigator April 2002.

SAS30022. A randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the efficacy and safety of the Fluticasone Propionate/Salmeterol Diskus combination product 250/50mcg once daily versus Fluticasone Propionate/Salmeterol Diskus combination product 100/50mcg twice daily versus Fluticasone Propionate Diskus 250mcg once daily versus placebo in symptomatic adolescent and adult subjects with asthma that is not controlled on short acting beta 2 agonists alone. GlaxoSmithKline. Investigator. 2002.

## **Research Continued:**

CFOR258D2307. A randomized, multicenter, placebo controlled, parallel group study, of four month duration per patient, to evaluate the safety and efficacy of treatment with 24mcg bid and 12mcg bid formoterol double blind and 12mcg bid formoterol with additional on demand formoterol doses open label in adolescent and adult patients with persistent stable asthma. Novartis. Investigator. April 2002.

MEM-MD-06. Evaluation of the long term safety and efficacy of memantine in the treatment of chronic pain in patients with painful diabetic neuropathy. Forest Laboratories. Investigator. June 2002.

MEM-MD-06B. Evaluation of the long term safety and efficacy of memantine in the treatment of chronic pain in patients with painful diabetic neuropathy. Forest Laboratories. Investigator. 2002.

ZOL446H2310 (zoledronic acid). Multinational, multicenter, double-blind, randomized, placebo controlled, parallel group study assessing the efficacy of intravenous zoledronic acid in preventing subsequent osteoporotic fractures after a hip fracture. Novartis. Investigator. June 2002.

MEM-MD-06C. Evaluation of the long term safety and efficacy of memantine in the treatment of chronic pain in patients with painful diabetic neuropathy. Forest Laboratories. Investigator. 2002.

SAS30031. A randomized, double-blind, 12 week trial evaluating the safety of Fluticasone Propionate/Salmeterol Diskus combination product 100/50mcg bid versus Fluticasone Propionate Diskus 100mcg bid in symptomatic pediatric subjects (4 – 11 years) with asthma. GlaxoSmithKline. Investigator. 2002.

BY217/FK1 020. 12 week treatment with 250mcg Roflumilast versus placebo in patients with asthma. Byk Gulden Pharmaceuticals. Investigator. 2002.

CFOR258D2307. A randomized, multicenter, placebo-controlled parallel group study of four months duration per patient to evaluate the safety and efficacy of treatment with 24 mcg bid and 12 mcg bid formoterol, double-blind, and 12 mcg bid formoterol with additional on-demand formoterol doses, open-label, in adolescent and adult patients with persistent stable asthma. Novartis. Investigator. October 2002.

BA16630B. Inhaled corticosteroid replacement study- Efficacy and safety of Ro-27-2441 in moderate persistent asthma. Phase II. Hoffmann La Roche. Investigator. Dec. 2002.

## Research Continued:

BA16631B. Dose –ranging study of Ro 27-2441 in patients with persistent asthma not treated with inhaled corticosteroids - Phase II. Hoffman La Roche. Investigator. Dec. 2002.

CCIB002K2302. A randomized, double-blind, multicenter, positive controlled, parallel group study to evaluate the safety and efficacy of Lotrel<sup>R</sup> (amlodipine/benazepril) compared to Zestoretic<sup>R</sup> (lisinopril/hydrochlorothiazide) in hypertensive patients. Novartis. Investigator. January 2003.

CVAH631C2301. A randomized, double-blind, multicenter, placebo-controlled, parallel group study to evaluate the efficacy and safety of valsartan (320mg) and hydrochlorothiazide (12.5mg and 25mg) combined and alone, valsartan 160mg and valsartan 160mg/hydrochlorothiazide 12.5mg in hypertensive patients. Novartis Pharmaceuticals. Investigator. 2003.

CHTF919A2306. A randomized, double-blind, placebo-controlled, parallel group, multicenter study to assess the efficacy and safety of repeated treatment with tegaserod 6mg bid and placebo in female patients with irritable bowel syndrome with constipation (IBS-C). Novartis. Investigator. July 2003.

CVAH631C2301. A 54-week open-label extension to a randomized, double-blind, multicenter, placebo-controlled, parallel group study to evaluate the efficacy and safety of valsartan (320mg) and hydrochlorothiazide (12.5mg and 25mg) combined and alone, valsartan 160mg and valsartan 160mg/hydrochlorothiazide 12.5mg in hypertensive patients. Novartis Pharmaceuticals. Investigator. 2003.

A3841012. Clinical utility of amlodipine/atorvastatin to improve concomitant cardiovascular risk factors of hypertension and dyslipidemia (Gemini). Pfizer. Investigator. 2003.

BY217/M2-023. A randomized, controlled study of roflumilast (250mcg and 500mcg) versus placebo in patients with asthma. A 24-week, multinational, double-blind, parallel group clinical study. Altana. Investigator. 2003

D5896C0005. A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT<sup>®</sup> pMDI administered either as fixed or as an adjustable regimen versus a fixed regimen of Advair<sup>™</sup> in subjects 12 years of age and older with asthma. Astra Zeneca. Investigator. 2003.

C02-009. A phase III, randomized, multicenter, allopurinol and placebo-controlled study assessing the safety and efficacy of oral febuxostat in subjects with gout. TAP Pharmaceuticals. Investigator. 2003

## Research Continued:

CCIB002 K2302. A randomized, double-blind, multicenter, positive controlled, parallel group study to evaluate the safety and efficacy of Lotrel (amlodipine/benazepril) compared to Zestoretic (lisinopril/hydrochlorothiazide) in hypertensive patients. Novartis Pharmaceuticals. Investigator. 2003.

066-00. A randomized, double-blind, active-comparator-controlled, parallel-group study to evaluate the safety of etoricoxib in patients with osteoarthritis or rheumatoid arthritis. Merck. Investigator. 2003.

MK-038. A multicenter, randomized, double-blind, placebo-controlled, “factorial” design study to evaluate the lipid-altering efficacy and safety of ezetimibe/simvastatin combination tablet in patients with primary hypercholesterolemia. Merck. Investigator. 2003.

D5896C00005. A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of Symbicort<sup>R</sup> pMDI administered either as fixed or as an adjustable regimen versus a fixed regimen of Advair<sup>R</sup> in subjects 12 years and older with asthma. AstraZeneca. Investigator. January 2004.

4522US/0011. A randomized, double-blind, placebo-controlled, multicenter, phase III study of Rosuvastatin (Crestor) 20 mg in the primary prevention of cardiovascular events among subjects with low levels of LDL-Cholesterol and elevated levels of C-reactive protein. AstraZeneca. Investigator. June 2004.

NN210005. A phase I, multicenter, randomized, parallel, double-blinded dose ranging, placebo-controlled study to compare antiviral effect, safety, tolerability and pharmacokinetics of four oral dosage regimens of GW695634G monotherapy versus placebo over 7 days in NNRTI-experienced HIV-1 infected adults. GlaxoSmithKline. Investigator. July 2004.

CCOX189A2369. A 52-week, international, multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial to compare retention on treatment, safety, tolerability and efficacy of lumiracoxib 100mg od, lumiracoxib 100mg bid and celecoxib 200mg od in patients with primary osteoarthritis of hip, knee, hand or spine. Novartis Pharmaceuticals. Investigator. July 2004.

D5896C00001. A randomized, double-blind, active-controlled, parallel-group, single-dummy, multicenter, 12 week study to assess the efficacy and safety of Symbicort pMDI 160/4.5 ug x 2 actuations once-daily (QD) compared to symbicort pMDI 80/4.5 ug x 2 actuations QD, Symbicort pMDI 80/4.5 ug x 2 actuations twice-daily (BID) and to budesonide pMDI 160 ug x 2 actuations QD in asthmatic subjects 12 years of age and older. AstraZeneca Pharmaceuticals LP. Investigator. July 2004.

## Research Continued:

L8890. Prospective, observational registry and patient survey of the management of men with symptomatic benign prostatic hyperplasia (BPH): BPH registry and patient survey. Sanofi. Investigator. September 2004.

HMR3647A/4019. A randomized, double-blind, parallel-group, multicenter study to compare clinical health outcomes of telithromycin versus azithromycin in outpatients with community-acquired lower respiratory tract infections. Aventis. Investigator. February 2005.

CCR102881. A Phase IIb, 96 week, randomized, partially double-blinded, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in combination with COMBIVIR (lamivudine and zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naïve adults. GlaxoSmithKline. Investigator. March 2005.

CCR104627. A screening protocol to determine eligibility for one of three Phase III treatment studies evaluating the efficacy and safety of GW873140 in R5-tropic and R5/X4-tropic HIV-1 infected, treatment-experienced subject with drug-resistant virus or an observational study in X4-tropic or non-phenotypeable HIV-1 infected, treatment-experienced subjects with drug-resistance virus. GlaxoSmithKline. Investigator. July 2005.

U10-04-02-007. A Randomized, double-blind, placebo-controlled, multicenter, pilot study to evaluate the safety and analgesic activity of M40403 co-administered with an opioid agent in a cancer pain model. Metaphore Pharmaceuticals. Investigator. July 2005.

CVAH631BUS04/A. A 28 week, multicenter, randomized, active controlled, parallel group study to evaluate the effects of Diovan HCT (160/12.5 mg) in comparison with hydrochlorothiazide (25 mg) monotherapy, for the treatment of patients with hypertension, uncontrolled by hydrochlorothiazide (12.5 mg) monotherapy. Novartis. Investigator. August 2005.

CSPP100A2328. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study comparing an eight week treatment of aliskiren 75 mg, 150 mg, and 300 mg to placebo in patients with essential hypertension. Novartis. Investigator. August 2005.

## Research Continued:

HPR20001. A phase IIb, randomized, multicenter, parallel group study to evaluate the short-term safety, pharmacokinetics and antiviral activity of four blinded dosing regimens of GW640385/ritonavir therapy compared to open-label current protease inhibitor therapy in HIV-1 infected, protease inhibitor experienced adults for 2 weeks with long-term evaluation (>48 weeks) of safety, pharmacokinetic and antiviral activity of selected GW640385/ritonavir dosing regimen(s) vs. a ritonavir-boosted, protease inhibitor containing regimen. GlaxoSmithKline. Investigator. October 2005.

TMC114-C211. A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. ARTEMIS TRIAL. Tibotec Pharmaceuticals Ltd. Investigator. November 2005.

TMC114-C226. Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options. Tibotec Pharmaceuticals Ltd. Investigator. November 2005.

M05-750. A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of fenofibric acid and atorvastatin calcium combination therapy to fenofibric acid and atorvastatin calcium monotherapy in subjects with mixed dyslipidemia. Abbott Laboratories. Investigator. December 2005.

M05-758. A long-term, open-label, safety extension study of the combination of fenofibric acid and statin therapy for subjects with mixed dyslipidemia. Abbott Laboratories. Investigator. December 2005.

D5899C00001. A 12 month double-blind, double-dummy, randomized parallel group, multicenter efficacy and safety study of SYMBICORT® pMDI 2 x 160/4.5 mcg bid and 2 x 80/4.5 mcg bid compared to Formoterol TBH 2 x 4.5 mcg bid and placebo in patients with COPD. AstraZeneca. Investigator. March 2006.

References available upon request